Találati lista | Tudóstér

001-es BibID:	BIBFORM099738
035-os BibID:	(WoS)000748218100001 (Scopus)85122675323
Első szerző:	Juhász Imre (belgyógyász)
Cím:	Afamin Levels and Their Correlation with Oxidative and Lipid Parameters in Non-diabetic, Obese Patients / Imre Juhász, Szilvia Ujfalusi, Ildikó Seres, Hajnalka Lőrincz, Viktória Evelin Varga, György Paragh Jr., Sándor Somodi, Mariann Harangi, György Paragh
Dátum:	2022
ISSN:	2218-273X
Megjegyzések:	Background: Afamin is a liver-produced bioactive protein and features α-and γ-tocopherol binding sites. Afamin levels are elevated in metabolic syndrome and obesity and correlate well with components of metabolic syndrome. Afamin concentrations, correlations between afamin and vitamin E, afamin and lipoprotein subfractions in non-diabetic, obese patients have not been fully examined. Methods: Fifty non-diabetic, morbidly obese patients and thirty-two healthy, normal-weight individuals were involved in our study. The afamin concentrations were measured by ELISA. Lipoprotein subfractions were determined with gel electrophoresis. Gas chromatography-mass spectrometry was used to measure α-and γ tocopherol levels. Results: Afamin concentrations were significantly higher in the obese patients compared to the healthy control (70.4 ± 12.8 vs. 47.6 ± 8.5 ?g/mL, p < 0.001). Positive correlations were found between afamin and fasting glucose, HbA1c, hsCRP, triglyceride, and oxidized LDL level, as well as the amount and ratio of small HDL subfractions. Negative correlations were observed between afamin and mean LDL size, as well as the amount and ratio of large HDL subfractions. After multiple regression analysis, HbA1c levels and small HDL turned out to be independent predictors of afamin. Conclusions: Afamin may be involved in the development of obesity-related oxidative stress via the development of insulin resistance and not by affecting alpha- and gamma-tocopherol levels.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Biomolecules. - 12 : 1 (2022), p. 1-11. -
További szerzők:	Ujfalusi Szilvia (1990-) (belgyógyász) Seres Ildikó (1954-) (biokémikus) Lőrincz Hajnalka (1986-) (biológus) Varga Viktória Evelin (1988-) (biológus) Paragh György Jr. (1978-) (bőrgyógyász) Somodi Sándor (1977-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász)
Pályázati támogatás:	NKFIH K115723 Egyéb GINOP-2.3.2-15-2016-00005 GINOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM072450
Első szerző:	Szentpéteri Anita (biológus)
Cím:	Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients / Anita Szentpéteri, Hajnalka Lőrincz, Sándor Somodi, Viktória Evelin Varga, György Paragh Jr., Ildikó Seres, György Paragh, Mariann Harangi
Dátum:	2018
ISSN:	1476-511X
Megjegyzések:	Background: Obestatin is a ghrelin-associated peptide, derived from preproghrelin. Although many of its effects are unclear, accumulating evidence supports positive actions on both metabolism and cardiovascular function. To date, level of obestatin and its correlations to the lipid subfractions in non-diabetic obese (NDO) patients have not been investigated. Methods: Fifty NDO patients (BMI: 41.96?8.6 kg/m2) and thirty-two normal-weight, age- and gender-matched healthy controls (BMI: 24.16?3.3 kg/m2) were enrolled into our study. Obestatin level was measured by ELISA. Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions, intermediate density lipoprotein (IDL) and very low-density lipoprotein (VLDL) levels and mean LDL size were detected by nongradient polyacrylamide gel electrophoresis (Lipoprint).Results: Serum level of obestatin was significantly lower in NDO patients compared to controls (3.01?0.5 vs. 3.29?0.6 ?g/ml, p<0.05). We found significant negative correlations between the level of obestatin and BMI (r=-0.33; p<0.001), level of serum glucose (r=-0.27, p<0.05), HbA1c (r=-0.38; p<0.001) and insulin (r=-0.34; p<0.05). Significant positive correlation was found between obestatin level and the levels of ApoA1 (r=0.25; p<0.05), large HDL subfraction ratio and level (r=0.23; p<0.05 and r=0.24; p<0.05), IDL (r=0.25 p<0.05) and mean LDL size (r=0.25; p<0.05). Serum VLDL ratio and level negatively correlated with obestatin (r=-0.32; p<0.01 and r=-0.21; p=0.05). In multiple regression analysis obestatin was predicted only by VLDL level.Conclusions: Based on our data, measurement of obestatin level in obesity may contribute to understand the interplay between gastrointestinal hormone secretion and metabolic alterations in obesity.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban obestatin metabolic syndrome diabetes obesity hyperlipidemia
Megjelenés:	Lipids in Health and Disease. - 17 : 1 (2018), p. 1-27. -
További szerzők:	Lőrincz Hajnalka (1986-) (biológus) Somodi Sándor (1977-) (belgyógyász) Varga Viktória Evelin (1988-) (biológus) Paragh György Jr. (1978-) (bőrgyógyász) Seres Ildikó (1954-) (biokémikus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus)
Pályázati támogatás:	GINOP-2.3.2-15-2016-00005 GINOP 115723 OTKA
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI Szerző által megadott URL
Borító:
Saját polcon: